All In Biotech

BLA 125527 · Bristol Myers Squibb

Opdivo

Nivolumab · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 4, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Mar 4, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,779

188 Phase 3, 304 recruiting

FAERS reports

97,932

87,480 serious, 25,065 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 4, 2015 Original approval · Type 9 - New indication submitted as distinct BLA, consolidated · priority review ReviewLetterLabel
2 products under this application
  • OPDIVO · NIVOLUMAB 40MG/4ML · INJECTABLE, INJECTION · Prescription
  • OPDIVO · NIVOLUMAB 100MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nivolumab" as an intervention, any sponsor and status, largest first.

All 1,779 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death12,098
  • malignant neoplasm progression9,963
  • off label use6,485
  • diarrhoea5,336
  • fatigue4,264
  • pyrexia3,792
  • intentional product use issue3,329
  • nausea3,233
  • rash3,143
  • decreased appetite2,949
  • dyspnoea2,709
  • pneumonia2,499

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20125
201341
2014140
20152,615
20167,163
20179,632
201810,908
201911,341
20208,904
20219,407
202210,069
20237,721
20247,628
20256,915
20265,442

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Opdivo (Nivolumab)

2024 spending

$50.3M

Beneficiaries

690

4,120 claims

Per beneficiary

$72,883

$308.87 per unit

View as table
YearSpending
2020$37,098,263
2021$33,651,451
2022$43,848,492
2023$51,314,795
2024$50,289,570

Part B: Opdivo (Nivolumab) · HCPCS J9299

2024 spending

$1.93B

Beneficiaries

26,951

176,422 claims

Per beneficiary

$71,752

2024 ASP limit $31.38 per unit

View as table
YearSpending
2020$1,586,651,124
2021$1,573,611,853
2022$1,849,938,540
2023$1,910,233,910
2024$1,933,800,338

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,745 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.